5s-12r-18r-trihydroxy-6z-8e-10e-14z-16e-eicosapentaenoic-acid and Neuralgia

Accumulating evidence indicates that activation of spinal cord microglia plays an important role in the genesis of neuropathic pain. Resolvin E1 (E1) is derived from omega-3 polyunsaturated fatty acid and exhibits potent anti-inflammatory, pro-resolution, and anti-nociceptive effects. We further examined whether RvE1 could reduce neuropathic pain and modulate spinal cord microglial activation. Intrathecal pre-treatment of RvE1 (100 ng) daily for 3 days partially prevented the development of nerve injury-induced mechanical allodynia and up-regulation of IBA-1 (microglial marker) and TNF-α in the spinal cord dorsal horn. Furthermore, intrathecal post-treatment of RvE1 (100 ng), 3 weeks after nerve injury, transiently reduced mechanical allodynia and heat hyperalgesia. Finally, RvE1 blocked lipopolisaccharide-induced microgliosis and TNF-α release in primary micoglial cultures. Our data suggest that RvE1 may attenuate neuropathic pain via inhibiting microglial signaling. Targeting the anti-inflammatory and pro-resolution lipid mediators may offer new options for preventing and treating neuropathic pain.

Topics: Animals; Behavior, Animal; Cells, Cultured; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Gliosis; Hyperalgesia; Immunohistochemistry; Injections, Spinal; Lipopolysaccharides; Macrophage Activation; Male; Mice; Microglia; Neuralgia; Peripheral Nerve Injuries; Real-Time Polymerase Chain Reaction; Signal Transduction; Spinal Cord; Spinal Cord Injuries; Tumor Necrosis Factor-alpha